TOG Review (RCOG Journal)

MRCOG Part 2

Urogynaecology and Pelvic Floor Problems

Management of refractory overactive bladder

Key Statistics

  • >50% — OAB failing 1ST-line treatment
  • 200/100 U — NICE onabotulinumtoxina dose
  • ~10% / ~20% — Botox retention / UTI rates

Don't-miss facts

  1. Refractory OAB has no agreed definition; 25–40% fail anticholinergics; MDT review mandatory before invasive therapy

  2. NICE botulinum toxin A: 200 units standard, 100 units option (lower retention risk, reduced success); urodynamic- proven detrusor overactivity required by NICE (not by the drug licence for 100 units)

  3. Injection technique: 10 U × 20 sites (200U) or 5 U × 20 sites (100U); effect lasts 3–6 months; only 10–15% need CIC

  4. Avoid aminoglycosides post-botulinum toxin – may potentiate toxin/muscle relaxant effect

  5. SNS: reoperation rate 33%; 9% need permanent removal; advanced evaluation → 70–90% progress to permanent implant vs 40–50% after peripheral nerve evaluation

  6. PTNS: 12 weekly × 30 min sessions; benefit significant only from 13 weeks, not 7 weeks

  7. Third-line surgery (diversion/clam cystoplasty) ~1% mortality; long-term catheter is a valid, often overlooked alternative

  8. Mirabegron (beta-3 agonist): contraindicated in uncontrolled hypertension; adverse effects tachycardia, UTI

Treatment ladder at a glance

1st line: lifestyle, PFMT, bladder retraining 2nd line: antimuscarinics / mirabegron Refractory: botulinum toxin A, SNS, PTNS

3rd line: diversion, clam cystoplasty, long-term catheter

Abbreviation Key

  • OAB — overactive bladder
  • UTI — urinary tract infection
  • ICS — International Continence Society
  • CIC — clean intermittent catheterisation
  • NICE — National Institute for Health and Care Excellence
  • MDT — multidisciplinary team
  • AUA — American Urological Association
  • RCT — randomised controlled trial
  • SNAP-25 — synaptosomal-associated protein 25
  • BMI — body mass index
  • SNS — sacral nerve stimulation
  • CI — confidence interval
  • PTNS — percutaneous (posterior) tibial nerve stimulation

Source: Wong J, Tincello DG. Management of refractory overactive bladder. The Obstetrician & Gynaecologist 2016;18:173–181. doi:10.1111/tog.12265

MRCOG AI is an independent educational tool. It is not affiliated with, endorsed by, or connected to the Royal College of Obstetricians and Gynaecologists (RCOG).

Included with a Pass Package

  • Audio overview of this guideline
  • Practice questions drawn from it
  • AI tutor answers grounded in its text
  • Your own annotations
Start free